Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201144
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rosa Carrillo, David de la | - |
dc.contributor.author | Suárez Cuartín, Guillermo | - |
dc.contributor.author | Sibila, Oriol | - |
dc.contributor.author | Golpe, Rafael | - |
dc.contributor.author | Girón, Rosa María | - |
dc.contributor.author | Martínez García, Miguel Ángel | - |
dc.date.accessioned | 2023-07-25T10:37:51Z | - |
dc.date.available | 2023-07-25T10:37:51Z | - |
dc.date.issued | 2023-05-20 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201144 | - |
dc.description.abstract | The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics. | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm12103577 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2023, vol. 12, num. 10 | - |
dc.relation.uri | https://doi.org/10.3390/jcm12103577 | - |
dc.rights | cc by (c) Rosa Carrillo, David de la et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Teràpia respiratòria | - |
dc.subject.classification | Antibiòtics | - |
dc.subject.other | Respiratory therapy | - |
dc.subject.other | Antibiotics | - |
dc.title | Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-17T11:21:29Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37240682 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-12-03577-v2.pdf | 1.04 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License